MRC1 and neoplasm: In this study, we examined a single-institution retrospective cohort of 11 pediatric high-grade astrocytic gliomas with matched pre- and post-treatment tumor specimens, including one previously published case from our institution of diffuse hemispheric glioma H3 G34-mutant that was found to have treatment-associated MMR deficiency and increased tumor mutation burden [11].